-Advertisement-
-Advertisement-
Neurology
Discontinuing high-efficacy therapy for older patients with MS raises relapse risk
A recent observational cohort study sheds light on the risks associated with discontinuing high-efficacy therapy (HET) for older patients with nonactive multiple sclerosis (MS). The findings provide crucial insights into treatment strategies for this demographic group. Below are the main takeaways. Discontinuing High-Efficacy Therapy (HET) Poses Risks: Stopping HET for...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved